OTCMKTS:PBSV Pharma-Bio Serv (PBSV) Stock Price, News & Analysis → Wall Street Icon: 'I'd Put 50% of My Kids' Inheritance in THIS stock' (From Stansberry Research) (Ad) Free PBSV Stock Alerts $0.53 -0.12 (-18.58%) (As of 06/12/2024 ET) Add Compare Share Share Today's Range$0.53▼$0.6950-Day Range$0.53▼$0.8952-Week Range$0.52▼$1.10Volume6,390 shsAverage Volume5,262 shsMarket Capitalization$12.08 millionP/E Ratio17.54Dividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartDividendEarningsFinancialsHeadlinesSEC FilingsShort InterestStock AnalysisChartDividendEarningsFinancialsHeadlinesSEC FilingsShort Interest Get Pharma-Bio Serv alerts: Email Address Ad Stansberry ResearchWall Street Icon: "I'd Put 50% of My Kids' Inheritance in THIS stock"Wall Street Icon Warns: "A Great Financial Reset is Underway" The man CNBC called "The Prophet" predicted the 2008 housing crisis and the 2022 sell-off… Now, he says that despite the bull market, he's worried older Americans are holding the WRONG stocks in their portfolios for this stage of their lives. So, he's urging folks to buy "America's No. 1 Legacy Stock," which could help them build wealth they could pass on for generations.Learn more here. About Pharma-Bio Serv Stock (OTCMKTS:PBSV)Pharma-Bio Serv, Inc. operates as a compliance and technology transfer services consulting firm in Puerto Rico, the United States, Europe, Brazil, and internationally. The company provides technical compliance consulting services comprising regulatory compliance, validation, technology transfer, engineering, project management, and process support for the pharmaceutical, chemical manufacturing, biotechnology, medical device, cosmetic, food industries, and allied products companies. Pharma-Bio Serv, Inc. was founded in 1993 and is headquartered in Dorado, Puerto Rico.Read More PBSV Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PBSV Stock News HeadlinesMay 18, 2024 | wsj.comPharma-Bio Serv Inc.May 14, 2024 | msn.comKörber Pharma and Siemens Take the Lead in ABI Research's MES Software for Pharmaceutical, Biotechnology, and Cell & Gene Manufacturing Competitive RankingMay 2, 2024 | markets.businessinsider.comBBIO Stock Earnings: BridgeBio Pharma Beats EPS, Beats Revenue for Q1 2024April 25, 2024 | markets.businessinsider.comDeep Dive Into Biomarin Pharmaceutical Stock: Analyst Perspectives (8 Ratings)April 25, 2024 | markets.businessinsider.comEQS-News: Marinomed Biotech AG enters Solv4U R&D collaboration with Brazilian pharmaceutical company Aché LaboratóriosApril 23, 2024 | markets.businessinsider.comBiomarin Pharmaceutical earnings preview: what Wall Street is expectingApril 16, 2024 | markets.businessinsider.comBuy Rating Affirmed for BioMarin Pharmaceutical Amidst Strong Sales Outlook and Optimized Market ExpectationsApril 9, 2024 | tmcnet.comSanguine Biosciences Affirms Superior Quality of its Biospecimen Services Using VERIF.i®, Scientist.com's Supplier Pre-assessment ProgramApril 3, 2024 | benzinga.comLooking Into Biomarin Pharmaceutical's Recent Short InterestMarch 19, 2024 | finance.yahoo.comPBSV Releases Quarterly ResultsMarch 19, 2024 | seekingalpha.comPharma-Bio Serv reports Q1 resultsMarch 4, 2024 | markets.businessinsider.comBuy Rating Affirmed for BridgeBio Pharma Amidst Strategic Bayer Collaboration and Promising Financial OutlookMarch 4, 2024 | markets.businessinsider.comMaintaining Hold on BridgeBio Pharma Amidst Bayer Partnership and Market UncertaintiesFebruary 26, 2024 | marketwatch.comBioMarin Pharmaceutical Gets DOJ Subpoena for Documents Related to Vimizim, Naglazyme -- UpdateFebruary 23, 2024 | markets.businessinsider.comStrong Voxzogo Performance Underpins Buy Rating for BioMarin PharmaceuticalJanuary 30, 2024 | finance.yahoo.comPBSV Expands Margins and MarketsJanuary 28, 2024 | msn.comJubilant Pharma Plans Stake Sale in Sofie Biosciences Amid Merger DealJanuary 9, 2024 | markets.businessinsider.comOptimistic Outlook: Buy Rating for BridgeBio Pharma with Promising Treatment Launches and Strategic Growth DriversJanuary 8, 2024 | seekingalpha.comBridgeBio Pharma's Robust Pipeline Could Benefit From A PartnerJanuary 3, 2024 | finance.yahoo.comPBSV Reward Shareholders with High YieldDecember 21, 2023 | finanznachrichten.dePharma-Bio Serv Inc.: Pharma-Bio Serv Announces Special DividendDecember 8, 2023 | msn.comAbbVie's on an Acquisition Binge. Could Your Favorite Biotech Stock Be Next?November 28, 2023 | markets.businessinsider.comBioMarin Pharma Reaches Agreement On Reimbursement Amount For ROCTAVIAN In GermanyNovember 7, 2023 | markets.businessinsider.comPromising Future for BridgeBio Pharma: Lebovitz’s Buy Rating Backed by Potential Blockbusters and Pipeline AssetsNovember 6, 2023 | markets.businessinsider.comBridgeBio Pharma Receives Buy Rating Amid Promising Drug Pipeline Developments and Strong Financial PositionSee More Headlines Receive PBSV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Pharma-Bio Serv and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/18/2024Today6/13/2024Fiscal Year End10/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorBusiness Services Industry Management consulting services Sub-IndustryN/A Current SymbolOTCMKTS:PBSV CUSIPN/A CIK1304161 Webwww.pharmabioserv.com Phone(787) 278-2709Fax787-796-5168Employees100Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)$0.03 Trailing P/E Ratio17.54 Forward P/E Ratio6.58 P/E GrowthN/ANet Income$1.31 million Net Margins4.05% Pretax Margin5.65% Return on Equity3.95% Return on Assets3.10% Debt Debt-to-Equity RatioN/A Current Ratio5.10 Quick Ratio5.10 Sales & Book Value Annual Sales$16.98 million Price / Sales0.71 Cash Flow$0.06 per share Price / Cash Flow9.17 Book Value$0.70 per share Price / Book0.75Miscellaneous Outstanding Shares22,960,000Free Float20,162,000Market Cap$12.08 million OptionableNot Optionable Beta0.53 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report Key ExecutivesMr. Victor Sanchez (Age 53)CEO, President & President of European Operations Comp: $323.67kMr. Pedro J. Lasanta (Age 64)CFO, VP of Finance & Administration and Secretary Comp: $225.6kMs. Elizabeth Plaza (Age 60)Founder & Senior Strategic Consultant Comp: $69.92kMs. Miriam Marrero M.B.A.Human Resources ManagerKey CompetitorsJuneeNASDAQ:JUNETSSOTCMKTS:TSSILichen ChinaNASDAQ:LICNIssuer DirectNYSE:ISDRLightbridgeNASDAQ:LTBRView All Competitors PBSV Stock Analysis - Frequently Asked Questions How have PBSV shares performed in 2024? Pharma-Bio Serv's stock was trading at $1.05 at the beginning of 2024. Since then, PBSV shares have decreased by 49.9% and is now trading at $0.5260. View the best growth stocks for 2024 here. Are investors shorting Pharma-Bio Serv? Pharma-Bio Serv saw a decrease in short interest in May. As of May 31st, there was short interest totaling 700 shares, a decrease of 86.0% from the May 15th total of 5,000 shares. Based on an average daily volume of 9,300 shares, the days-to-cover ratio is presently 0.1 days. View Pharma-Bio Serv's Short Interest. How were Pharma-Bio Serv's earnings last quarter? Pharma-Bio Serv, Inc. (OTCMKTS:PBSV) issued its earnings results on Monday, March, 18th. The company reported ($0.01) earnings per share for the quarter, missing analysts' consensus estimates of $0.02 by $0.03. The company had revenue of $2.38 million for the quarter, compared to the consensus estimate of $5 million. Pharma-Bio Serv had a net margin of 4.05% and a trailing twelve-month return on equity of 3.95%. How often does Pharma-Bio Serv pay dividends? What is the dividend yield for Pharma-Bio Serv? Pharma-Bio Serv declared a dividend on Thursday, December 21st. Investors of record on Tuesday, January 30th will be paid a dividend of $0.075 per share on Thursday, February 15th. The ex-dividend date is Monday, January 29th. Read our dividend analysis for PBSV. What other stocks do shareholders of Pharma-Bio Serv own? Based on aggregate information from My MarketBeat watchlists, some companies that other Pharma-Bio Serv investors own include Zynerba Pharmaceuticals (ZYNE), Allena Pharmaceuticals (ALNA), AstroNova (ALOT), Oracle (ORCL), AT&T (T), Yintech Investment (YIN), Aeglea BioTherapeutics (AGLE), Ampliphi Biosciences (APHB), Carnival Co. & (CCL) and Earthstone Energy (ESTE). How do I buy shares of Pharma-Bio Serv? Shares of PBSV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:PBSV) was last updated on 6/13/2024 by MarketBeat.com Staff From Our PartnersGold Prices Surge and This $0.32 Stock Is Reaping The RewardsGold prices are on the rise. This surge in gold prices is great news for gold mining stocks. Especially ...Market JAR | SponsoredEstee Lauder, MAC, and other beauty brands are raving about this emerging NYSE AI companyA Little-known NYSE Company is Empowering the Beauty Industry with Innovative AI and AR Tools.Financial Markets Daily | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredNo Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for FreeOptimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analys...Hedgeye | SponsoredPlease, take this warning seriously todayWall Street Legend Warns "Mass Bank Run" is Coming Man who predicted 2023 bank run warns it could soon get ...Chaikin Analytics | SponsoredAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | SponsoredThe Only Energy Play You Should Be Looking AtOpen AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has alr...Wealthpin Pro | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pharma-Bio Serv, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Pharma-Bio Serv With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
